Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ALK |
| Variant | R1275L |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | ALK R1275L lies within the protein kinase domain of the Alk protein (UniProt.org). R1275L has been identified in the scientific literature (PMID: 27888620), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, May 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
ALK mutant ALK R1275X ALK R1275L |
| Transcript | NM_004304.5 |
| gDNA | chr2:g.29209798C>A |
| cDNA | c.3824G>T |
| Protein | p.R1275L |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004304.4 | chr2:g.29209798C>A | c.3824G>T | p.R1275L | RefSeq | GRCh38/hg38 |
| NM_004304.5 | chr2:g.29209798C>A | c.3824G>T | p.R1275L | RefSeq | GRCh38/hg38 |
| NM_004304 | chr2:g.29209798C>A | c.3824G>T | p.R1275L | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK R1275L | neuroblastoma | predicted - sensitive | Crizotinib | Case Reports/Case Series | Actionable | In a Phase I/II trial, Xalkori (crizotinib) treatment was well-tolerated and resulted in stable disease in a pediatric patient with neuroblastoma harboring ALK R1275L who stayed on treatment for 4 cycles (PMID: 23598171; NCT00939770). | 23598171 |